作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
摘要:
癌胚抗原相关细胞黏附分子1 (carcinoembryonic antigen-related cell adhesion molecule 1，CEACAM1) 是一种免疫球蛋白超家族的跨膜蛋白，参与介导细胞黏附、组织转移、免疫反应控制以及机体代谢平衡。研究表明, CEACAM1主要通过促进胰岛素清除以防止脂肪沉积, 从而对肝脏发挥保护作用。CEACAM1表达水平下调会导致胰岛素抵抗状态发生恶性循环并加重代谢紊乱。由于CEACAM1在控制代谢功能障碍相关脂肪性肝病(metabolic dysfunction-associated steatotic liver disease, MASLD) 中的关键地位，刺激其作用途径或调节其表达水平有望成为MASLD的治疗新方法。本文就CEACAM1在MASLD中的有关研究进展作一综述。
-
关键词:
- 代谢功能障碍相关脂肪性肝病 /
- 癌胚抗原相关细胞黏附分子1 /
- 胰岛素清除 /
- 脂质代谢
Abstract:Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a transmembrane protein of the immunoglobulin superfamily, is involved in mediating cell adhesion, tissue metastasis, control of immune response, and metabolic homeostasis. Studies have shown that CEACAM1 protects the liver by promoting insulin clearance and preventing fat deposition. The down-regulation of the CEACAM1 expression level leads to a vicious cycle of insulin resistance and aggravates metabolic disorders. As CEACAM1 is critical in controlling metabolic dysfunction-associated steatotic liver disease (MASLD), stimulating its pathway or regulating its expression level might be a potential new therapeutic approach for MASLD. In this paper, therefore, we summarize the research progress of CEACAM1 in MASLD.
-
经过一天烈日的炙烤，住院部外面的地表温度已经高达40 ℃，进进出出需要加强监护的患者还在不断增加，面对监护室内堆积如山的病患，大家的心情已经烦躁不安。高速周转的病房似乎又经历了一波“大洗牌”，病床上躺着不同的面孔，交班正仔细且有序地进行着。“号外……又有新病人要从急诊科转入，目前鼻导管10 L/min吸氧中，呼吸困难，需要重新评估插管指征......”值班护士小罗一边接听着电话，一边冲大家喊道。此刻空气仿佛凝住了一般，最尴尬的事情莫过如此——在交班时要来病人。“大家先交班，速战速决，准备收病人......”作为今天当值的高年资主治医师，我立刻说道。
伴随着转运车的声音，病人送来了，大家立刻围了上去，按照平时标准动作过床、吸氧、完成心电监护连接。我走到病床边，那是一位白发苍苍、胸前皮下还隐约有一枚“勋章”的爷爷，一看心电监护，我本能地反应那枚东西应该是心脏永久起搏器。为了判断病人意识及症状，我拍了拍老人肩膀，问道：“爷爷，您知道这是在哪儿吗？”老人没有回答，但是眼睛在不停地转动，嘴巴似乎要表达什么，带着一点儿北方口音，但听得不太清楚。我瞬时像明白了什么，于是俯下身去对着他的耳朵大声喊道：“爷爷，您知道这是在哪儿吗？您是不是听得不太清楚？”老人摇了摇头，又点了点头。
此时，我身旁一位经验丰富的“老医生”冲我扬了扬手中的听诊器听筒，我第一反应是她要听诊，于是连忙说道：“我来吧。”但她却直接把听头给爷爷戴上了，并对着听筒大声说道：“老爷子，这样能听清吗？”老人喃喃地回答：“听清了，听清了……”慢慢地，他紧崩的神情似乎也逐渐舒展开来。经过一系列问诊和针对性的处理后，爷爷慢慢睡着了。
病人急性呼吸窘迫的病因尚未完全明确，依然有病情随时加重的危险，依照惯例，我们立即联系家属了解老人的病史并进行谈话签字。通过与家属充分沟通，我们了解到了爷爷的慢性病史以及本次发病的诱因，还得知爷爷听力不好，这几天辗转各大医院，一直没休息好，病情也越来越重了。好在经过我们悉心的治疗和照顾，两周后爷爷终于出院了！
门诊复诊时，我看到爷爷耳朵上多了一副助听器，便打趣道：“爷爷，现在声音清楚多了吧？”爷爷笑着回答：“这玩意儿还是没有你们给我戴的东西听得清楚。”我和家属听完都哈哈大笑起来……
后记
听诊器的发明已有近200年的历史，其除了可以帮助医生完成重要的听诊检查外，在某些情况下还可以成为与病人沟通的桥梁。从法国医生雷奈克为了诊治患者，第一次提出“听诊器”的概念，到吴孟超院士在冬天查房时先用双手捂热听诊器再为患者听诊，再到为了能让患者听清楚，发现听诊器的新用途……不同听诊器的故事中，有不同的主人公以及不同的场景，但伴随的都是那份来自医生的爱，那份给予患者温暖的爱。病人与医生之间的第一步，是沟通，是了解，但病人在任何时候和任何状态下，都一定是需要帮助的那个人。任何人在面对身体的病痛时，或是因为没有足够专业的知识，或是因为疾病带来的切肤之痛，无论是酸胀、麻木、疼痛、无力，还是其他任何一种异样的感觉，都会让其内心产生对于异常表现的无限猜测以及随之而来的焦虑、恐慌。初入医学院时的我，心里想的只是如何掌握高精尖的各种医学技术，如何把病看好。进入医院工作多年以后，特别是在经历新型冠状病毒感染疫情后，我深切地体会到，不管医生的技术有多精湛，医疗水平有多高超，医生的关怀和援助永远都是病人最坚实的情感堡垒。治病一定是依靠科学，但让病人感觉到舒服却更需要医生对于患者那颗帮助的心。从医和患这层关系构建起来的那一刻起，他们就不该是对立的，而是共生的，更是共情的，感同身受、同气连枝才是医治疾病的起点，更是每一个合格医生毕生追求的终点。
临床医生正如其名字一样，需要站在床边仔细观察病人。观察的目的除正确诊断病情外，更重要的是察觉病人最需要的帮助是什么。故事中的老人一直处于听不清周围声音的状态，这时候病人可能会感到恐惧与烦躁，甚至会导致病情恶化，而一次仔细的观察就能够使问题迎刃而解。一个小小的听诊器，以及听诊器带来的这份“逆向思维”，彰显的不仅是一种临床采集病史的技巧，更是医生把心打开，试图去侧耳倾听病人诉说的耐心，以及尽其所能去关爱病人的慈悲。
因此，听诊器的故事，讲述的不是一种疾病的诊断，更不是一个病例的转归，听诊器联通的亦非症状与诊断，心跳与鼓膜，而是受伤的心和呵护的手，告诉我你哪里不舒服，我一定会想办法听到你的诉说，也一定会陪着你直到疾病消散。把痛苦告诉我，把希望传给你，这才是听诊器的真正意义所在，才是医生和病人最正确的相处方式。一如美国医生特鲁多对医生这个职业的经典描述——有时是治愈，常常是帮助，总是去安慰！
-
![]()
图 1 CEACAM1在MASLD发生发展中的作用机制
MASLD(metabolic dysfunction-associated steatotic liver disease): 代谢功能障碍相关脂肪性肝病；MASH(metabolic dysfunction-associated steatohepatitis): 代谢功能障碍相关脂肪性肝炎；FFAs(free fatty acids): 游离脂肪酸；TG(triglyceride): 甘油三酯；VLDL(very low-density lipoprotein): 极低密度脂蛋白；ET-1(endothelin-1): 内皮素-1；PDGF-B(platelet derived growth factor-B): 血小板源性生长因子B；IR(insulin resistance): 胰岛素抵抗；TNF-α(tumor necrosis factor-α): 肿瘤坏死因子α；IL(interleukin): 白细胞介素；IFN-γ(interferon-γ): 干扰素-γ；HFD(high fat die): 高脂饮食；Obese: 肥胖；Fat: 脂肪；FASN(fatty acid synthase): 脂肪酸合成酶；FGF21(fibroblast growth factor 21): 成纤维细胞生长因子21；CEACAM1(carcinoembryonic antigen-related cell adhesion molecule 1): 癌胚抗原相关细胞黏附分子1；Insulin level: 胰岛素水平；IRS-1(insulin receptor substrate 1): 胰岛素受体底物-1；T-cell: T细胞；Intestinal flora: 肠道菌群；PPAR(peroxisome-proliferator-activated receptor): 过氧化物酶体增殖物激活受体；Exenatide: 艾塞那肽
Figure 1. Mechanism of CEACAM1 in the occurrence and development of MASLD
-
[1] Younossi Z M, Golabi P, Paik J M, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347. DOI: 10.1097/HEP.0000000000000004
[2] Loomba R, Wong V W S. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease[J]. Aliment Pharmacol Ther, 2024, 59(2): 150-156. DOI: 10.1111/apt.17846
[3] Harrison S A, Dubourg J, Knott M, et al. Hyperinsuline-mia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease[J/OL]. Hepatology, 2023. doi: 10.1097/hep.0000000000000710.
[4] Yanai H, Adachi H, Hakoshima M, et al. Metabolic- dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments[J]. Int J Mol Sci, 2023, 24(20): 15473. DOI: 10.3390/ijms242015473
[5] Kube-Golovin I, Lyndin M, Wiesehöfer M, et al. CEACAM expression in an in-vitro prostatitis model[J]. Front Immunol, 2023, 14: 1236343. DOI: 10.3389/fimmu.2023.1236343
[6] Thomas J, Klebanov A, John S, et al. CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens[J]. Genes Cancer, 2023, 14: 12-29. DOI: 10.18632/genesandcancer.230
[7] Lee W. The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes[J]. Diagn Pathol, 2011, 6(1): 40. DOI: 10.1186/1746-1596-6-40
[8] Heinrich G, Ghadieh H E, Ghanem S S, et al. Loss of hepatic CEACAM1: a unifying mechanism linking insulin resistance to obesity and non-alcoholic fatty liver disease[J]. Front Endocrinol (Lausanne), 2017, 8: 8.
[9] Lee W H, Najjar S M, Kahn C R, et al. Hepatic insulin receptor: new views on the mechanisms of liver disease[J]. Metabolism, 2023, 145: 155607. DOI: 10.1016/j.metabol.2023.155607
[10] Russo L, Muturi H T, Ghadieh H E, et al. Liver-specific rescuing of CEACAM1 reverses endothelial and cardi-ovascular abnormalities in male mice with null deletion of Ceacam1 gene[J]. Mol Metab, 2018, 9: 98-113. DOI: 10.1016/j.molmet.2018.01.009
[11] Hajihassan Z, Mohammadpour Saray M, Yaseri A. Engineering a CEACAM1 variant with the increased binding affinity to TIM-3 receptor[J]. Iran Biomed J, 2023, 27(4): 191-198.
[12] Dery K J, Kojima H, Kageyama S, et al. Alternative splicing of CEACAM1 by hypoxia-inducible factor-1α enhances tolerance to hepatic ischemia in mice and humans[J]. Sci Transl Med, 2023, 15(707): eadf2059. DOI: 10.1126/scitranslmed.adf2059
[13] 刘传, 李丽娟, 王嵘, 等. CEACAM5在肺腺癌中的表达及临床意义[J]. 临床肺科杂志, 2022, 27(2): 256-261. DOI: 10.3969/j.issn.1009-6663.2022.02.020 Liu C, Li L J, Wang R, et al. Expression and clinical significance of CEACAM5 in lung adenocarcinoma[J]. J Clin Pulm Med, 2022, 27(2): 256-261. DOI: 10.3969/j.issn.1009-6663.2022.02.020
[14] 马凯, 王鸽, 孙建兵, 等. HopQ与人CEACAM1相互作用的研究进展[J]. 医学综述, 2019, 25(17): 3433-3437. DOI: 10.3969/j.issn.1006-2084.2019.17.020 Ma K, Wang G, Sun J B, et al. Research progress of HopQ interaction with human CEACAM1[J]. Med Recapitulate, 2019, 25(17): 3433-3437. DOI: 10.3969/j.issn.1006-2084.2019.17.020
[15] Fan Y J, Yan Z P, Li T T, et al. Primordial drivers of diabetes heart disease: comprehensive insights into insulin resistance[J]. Diabetes Metab J, 2024, 48(1): 19-36. DOI: 10.4093/dmj.2023.0110
[16] Schwärzler J, Grabherr F, Grander C, et al. The pathophysiology of MASLD: an immunometabolic perspective[J]. Expert Rev Clin Immunol, 2024, 20(4): 375-386. DOI: 10.1080/1744666X.2023.2294046
[17] Vesković M, Šutulović N, Hrnčić D, et al. The interconnection between hepatic insulin resistance and metabolic dysfunction-associated steatotic liver disease-the transition from an adipocentric to liver-centric approach[J]. Curr Issues Mol Biol, 2023, 45(11): 9084-9102. DOI: 10.3390/cimb45110570
[18] Margolis R N, Taylor S I, Seminara D, et al. Identification of pp120, an endogenous substrate for the hepatocyte insulin receptor tyrosine kinase, as an integral membrane glycoprotein of the bile canalicular domain[J]. Proc Natl Acad Sci U S A, 1988, 85(19): 7256-7259. DOI: 10.1073/pnas.85.19.7256
[19] Najjar S M. Regulation of insulin action by CEACAM1[J]. Trends Endocrinol Metab, 2002, 13(6): 240-245. DOI: 10.1016/S1043-2760(02)00608-2
[20] Choice C V, Howard M J, Poy M N, et al. Insulin stimulates pp120 endocytosis in cells co-expressing insulin receptors[J]. J Biol Chem, 1998, 273(35): 22194-22200. DOI: 10.1074/jbc.273.35.22194
[21] Bergman R N, Kabir M, Ader M. The physiology of insulin clearance[J]. Int J Mol Sci, 2022, 23(3): 1826. DOI: 10.3390/ijms23031826
[22] Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis[J]. Hepatology, 2014, 59(6): 2178-2187. DOI: 10.1002/hep.26988
[23] De Vries M, El-Morabit F, Van Erpecum K J, et al. Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes[J]. Eur J Intern Med, 2022, 100: 77-82. DOI: 10.1016/j.ejim.2022.03.025
[24] De Vries M, Westerink J, Kaasjager K H A H, et al. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2020, 105(12): 3842-3853. DOI: 10.1210/clinem/dgaa575
[25] Poy M N, Ruch R J, Fernstrom M A, et al. Shc and CEACAM1 interact to regulate the mitogenic action of insulin[J]. J Biol Chem, 2002, 277(2): 1076-1084. DOI: 10.1074/jbc.M108415200
[26] Yousef A A, Behiry E G, Allah W M A, et al. IRS-1 genetic polymorphism (r.2963G > A) in type 2 diabetes mellitus patients associated with insulin resistance[J]. Appl Clin Genet, 2018, 11: 99-106. DOI: 10.2147/TACG.S171096
[27] Poy M N, Yang Y, Rezaei K, et al. CEACAM1 regulates insulin clearance in liver[J]. Nat Genet, 2002, 30(3): 270-276. DOI: 10.1038/ng840
[28] Nagaishi T, Pao L, Lin S H, et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms[J]. Immunity, 2006, 25(5): 769-781. DOI: 10.1016/j.immuni.2006.08.026
[29] Mahmoud A M, Szczurek M R, Blackburn B K, et al. Hyperinsulinemia augments endothelin-1 protein expression and impairs vasodilation of human skeletal muscle arterioles[J]. Physiol Rep, 2016, 4(16): e12895. DOI: 10.14814/phy2.12895
[30] Abu Helal R, Muturi H T, Lee A D, et al. Aortic fibrosis in insulin-sensitive mice with endothelial cell-specific deletion of Ceacam1 gene[J]. Int J Mol Sci, 2022, 23(8): 4335. DOI: 10.3390/ijms23084335
[31] Muturi H T, Ghadieh H E, Abdolahipour R, et al. Loss of CEACAM1 in endothelial cells causes hepatic fibrosis[J]. Metabolism, 2023, 144: 155562. DOI: 10.1016/j.metabol.2023.155562
[32] Helal R A, Russo L, Ghadieh H E, et al. Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1[J]. Metabolism, 2021, 121: 154801. DOI: 10.1016/j.metabol.2021.154801
[33] Yan M L, Li H, Xu S Y, et al. Targeting endothelial necroptosis disrupts profibrotic endothelial-hepatic stellate cells crosstalk to alleviate liver fibrosis in nonalcoholic steatohepatitis[J]. Int J Mol Sci, 2023, 24(14): 11313. DOI: 10.3390/ijms241411313
[34] Laurenti M C, Dalla Man C, Varghese R T, et al. Insulin pulse characteristics and insulin action in non-diabetic humans[J]. J Clin Endocrinol Metab, 2021, 106(6): 1702-1709. DOI: 10.1210/clinem/dgab100
[35] DeBose-Boyd R A, Ye J. SREBPs in lipid metabolism, insulin signaling, and beyond[J]. Trends Biochem Sci, 2018, 43(5): 358-368. DOI: 10.1016/j.tibs.2018.01.005
[36] Matveyenko A V, Liuwantara D, Gurlo T, et al. Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling[J]. Diabetes, 2012, 61(9): 2269-2279. DOI: 10.2337/db11-1462
[37] Ramakrishnan S K, Khuder S S, Al-Share Q Y, et al. PPARα (peroxisome proliferator-activated receptor α) activation reduces hepatic CEACAM1 protein expression to regulate fatty acid oxidation during fasting-refeeding transition[J]. J Biol Chem, 2016, 291(15): 8121-8129. DOI: 10.1074/jbc.M116.714014
[38] Najjar S M, Caprio S, Gastaldelli A. Insulin clearance in health and disease[J]. Annu Rev Physiol, 2023, 85: 363-381. DOI: 10.1146/annurev-physiol-031622-043133
[39] Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD-more than inflammation[J]. Nat Rev Endocrinol, 2022, 18(8): 461-472. DOI: 10.1038/s41574-022-00675-6
[40] Ruck L, Wiegand S, Kühnen P. Relevance and consequence of chronic inflammation for obesity development[J]. Mol Cell Pediatr, 2023, 10(1): 16. DOI: 10.1186/s40348-023-00170-6
[41] Hayakawa F, Soga K, Fujino J, et al. Utility of ultrasonography in a mouse model of non-alcoholic steatohepatitis induced by a choline-deficient, high-fat diet and dextran sulfate sodium[J]. Biochem Biophys Rep, 2023, 36: 101575.
[42] Kakino S, Ohki T, Nakayama H, et al. Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model[J]. Horm Metab Res, 2018, 50(1): 80-87. DOI: 10.1055/s-0043-118666
[43] DeAngelis A M, Heinrich G, Dai T, et al. Carcinoembry-onic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism[J]. Diabetes, 2008, 57(9): 2296-2303. DOI: 10.2337/db08-0379
[44] Park S Y, Cho Y R, Kim H J, et al. Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1[J]. Am J Physiol Endocrinol Metab, 2006, 291(3): E517-E524.
[45] Al-Share Q Y, DeAngelis A M, Lester S G, et al. Forced hepatic overexpression of CEACAM1 curtails Diet-Induced insulin resistance[J]. Diabetes, 2015, 64(8): 2780-2790. DOI: 10.2337/db14-1772
[46] Wang Z Y, Sun T T, Yu J J, et al. FGF21: a sharp weapon in the process of exercise to improve NAFLD[J]. Front Biosci (Landmark Ed), 2023, 28(12): 351. DOI: 10.31083/j.fbl2812351
[47] Bakker L E H, Van Schinkel L D, Guigas B, et al. A 5-day high-fat, high-calorie diet impairs insulin sensitivity in healthy, young South Asian men but not in Caucasian men[J]. Diabetes, 2014, 63(1): 248-258. DOI: 10.2337/db13-0696
[48] Pezzino S, Sofia M, Mazzone C, et al. Exploring public interest in gut microbiome dysbiosis, NAFLD, and probiotics using Google Trends[J]. Sci Rep, 2024, 14(1): 799. DOI: 10.1038/s41598-023-50190-5
[49] Park D J, Sung P S, Kim J H, et al. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1[J]. J Immunother Cancer, 2020, 8(1): e000301. DOI: 10.1136/jitc-2019-000301
[50] Khairnar V, Duhan V, Patil A M, et al. CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection[J]. Nat Commun, 2018, 9(1): 2561. DOI: 10.1038/s41467-018-04832-2
[51] Adams D H, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease[J]. Nat Rev Immunol, 2006, 6(3): 244-251. DOI: 10.1038/nri1784
[52] He R H, Zhao S B, Cui M Y, et al. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations[J]. Front Immunol, 2023, 14: 1234535. DOI: 10.3389/fimmu.2023.1234535
[53] Horst A K, Wegscheid C, Schaefers C, et al. Carcinoembryonic antigen-related cell adhesion molecule 1 controls IL-2-dependent regulatory T-cell induction in immune-mediated hepatitis in mice[J]. Hepatology, 2018, 68(1): 200-214. DOI: 10.1002/hep.29812
[54] Vallianou N, Christodoulatos G S, Karampela I, et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives[J]. Biomolecules, 2021, 12(1): 56. DOI: 10.3390/biom12010056
[55] Chen L F, Chen Z G, Baker K, et al. The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction[J]. Immunity, 2012, 37(5): 930-946. DOI: 10.1016/j.immuni.2012.07.016
[56] Gruzdev S K, Podoprigora I V, Gizinger O A. Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets[J]. Arch Microbiol, 2024, 206(2): 62. DOI: 10.1007/s00203-023-03752-0
[57] Najjar S M, Perdomo G. Hepatic insulin clearance: mechanism and physiology[J]. Physiology (Bethesda), 2019, 34(3): 198-215.
[58] Salehi M, Aulinger B, Prigeon R L, et al. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes[J]. Diabetes, 2010, 59(6): 1330-1337. DOI: 10.2337/db09-1253
[59] Ghadieh H E, Muturi H T, Russo L, et al. Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis[J]. Hepatol Commun, 2018, 2(1): 35-47. DOI: 10.1002/hep4.1117
[60] Ghadieh H E, Muturi H T, Najjar S M. Exenatide prevents diet-induced hepatocellular injury in a CEACAM1-dependent mechanism[J]. J Diabetes Treat, 2017, 2017(4): JDBT-133.
-
期刊类型引用(1)
1. 刘敏，杨金苹，赵金颜，乔建红. 老年共病患者自我感知老化、抑郁情绪与生活质量的相关性研究. 心理月刊. 2024(21): 58-60 . 
百度学术
其他类型引用(0)
下载:
计量
- 文章访问数: 1282
- HTML全文浏览量: 46
- PDF下载量: 41
- 被引次数: 1
